Waystar (NASDAQ:WAY) Stock Price Target Lowered at TD Cowen

Waystar (NASDAQ:WAY) had its price objective reduced by research analysts at TD Cowen from $42.00 to $39.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price objective points to a potential upside of 41.87% from the company’s current price.

A number of other equities research analysts have also recently commented on WAY. Morgan Stanley reissued an “equal weight” rating and set a $28.00 price target on shares of Waystar in a report on Wednesday, September 16th. Weiss Ratings raised Waystar from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 2nd. KeyCorp increased their target price on Waystar from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Canaccord Genuity Group lifted their target price on Waystar from $33.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Barclays cut Waystar from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $27.00 to $30.00 in a report on Tuesday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Waystar has an average rating of “Moderate Buy” and an average target price of $35.14.

Waystar Price Performance

Shares of NASDAQ WAY traded down $0.65 during midday trading on Tuesday, reaching $27.49. The stock had a trading volume of 880,066 shares, compared to its average volume of 2,531,574. The company has a market capitalization of $5.27 billion, a price-to-earnings ratio of 39.05, a price-to-earnings-growth ratio of 1.13 and a beta of 0.18. Waystar has a 12-month low of $17.26 and a 12-month high of $37.71. The stock has a 50-day moving average of $26.23 and a 200-day moving average of $23.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.85 and a current ratio of 1.85.

Waystar (NASDAQ:WAY) last released its earnings results on Monday, November 2nd. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $325.62 million for the quarter, compared to analysts’ expectations of $323.43 million. Waystar had a net margin of 11.18% and a return on equity of 7.03%. Waystar’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.37 EPS. As a group, research analysts anticipate that Waystar will post 1.47 EPS for the current fiscal year.

Insider Buying and Selling

In other Waystar news, CEO Matthew Hawkins sold 82,500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $26.23, for a total transaction of $2,163,975.00. Following the completion of the transaction, the chief executive officer owned 1,804,794 shares in the company, valued at $47,339,746.62. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 247,500 shares of company stock worth $6,370,499 over the last three months. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Waystar

Hedge funds have recently modified their holdings of the company. Canada Pension Plan Investment Board purchased a new position in shares of Waystar in the second quarter valued at $390,593,000. BlackRock Inc. bought a new stake in Waystar in the second quarter worth $357,950,000. Advent International L.P. purchased a new stake in Waystar during the second quarter valued at $227,060,000. Jupiter Topco LLC purchased a new stake in Waystar during the second quarter valued at $58,960,000. Finally, Bank of America Corp DE purchased a new stake in Waystar during the second quarter valued at $53,031,000.

Key Headlines Impacting Waystar

Here are the key news stories impacting Waystar this week:

• Positive Sentiment: Waystar reported third-quarter revenue of $325.6 million, up 21% from a year earlier, while non-GAAP EPS of $0.44 exceeded the $0.41 consensus estimate. Adjusted EBITDA margin was 43%, and net income reached $31.0 million. Waystar Reports Third Quarter 2026 Results
• Positive Sentiment: Canaccord Genuity raised its price target from $33 to $34 and assigned a Buy rating, indicating analyst confidence in Waystar’s longer-term growth prospects. Canaccord Genuity Group recommendations
• Neutral Sentiment: Management provided fiscal 2026 EPS guidance of $1.63-$1.71, with the low end matching consensus, and revenue guidance of approximately $1.3 billion, also broadly in line with expectations.
• Positive Sentiment: Separate coverage indicated that Waystar raised its adjusted EBITDA outlook to approximately $543 million-$549 million, suggesting continued operating leverage despite the more measured revenue outlook. Waystar forecasts revenue and adjusted EBITDA outlook
• Negative Sentiment: The full-year forecast did not clearly exceed Wall Street expectations; reported revenue guidance of $1.277 billion-$1.287 billion in some coverage was below the approximately $1.3 billion consensus figure. That limited guidance upside may have prompted profit-taking even after the quarterly beat. Waystar third-quarter earnings results

About Waystar

Waystar Holding Corp. is a healthcare technology company that provides cloud-based software designed to simplify administrative and financial processes across the healthcare industry. Its platform connects healthcare providers, health plans and patients, helping organizations manage revenue cycle operations and improve the flow of information and payments.

The company’s products and services include electronic claims management, eligibility and benefits verification, prior authorization, payment integrity, denial management, patient estimates and payments, billing automation, and healthcare analytics.